CERS reports Q1 2026 results after the close today — and the setup is unusually charged. A significant new supply contract sits alongside a recent cluster of insider selling, a short position that has grown materially over the past month, and a track record at earnings that has consistently punished longs.
The most concrete positive of the week arrived Monday, when Cerus announced a four-year supply agreement with Établissement Français du Sang — France's national blood establishment — for its INTERCEPT Blood System platelet pathogen inactivation platform. The deal is a meaningful contract extension into one of Europe's largest public health procurement systems and adds duration to the company's revenue visibility. The stock is up just over 2% on the week and 11% over the past month, trading at $1.97. The France contract is the clearest explanation for that recovery.
The short interest picture, however, has shifted in a way that complicates the bullish reading. Short interest climbed 41% over the past month, reaching 5.9% of the free float — a level that, while not extreme, represents a meaningful build from where it was in mid-March. Monday's session saw a sharp intraday reversal: shorts declined roughly 20% on April 28 after a spike to 14.1 million shares the previous day, suggesting some fast-money covering around the France announcement. The borrow market remains loose. Cost to borrow has fallen a third over the past month to just 0.34%, and availability is high — nothing in the lending market points to a squeeze setup. The ORTEX short score eased from 59.5 on Monday to 51.4 by Tuesday, still neutral but tracking the choppiness.
Options positioning has turned decidedly more bullish than the norm. The put/call ratio has dropped to just 0.10, well below its 20-day average of 0.25 and close to the 52-week low of 0.04. That is nearly 1.3 standard deviations below average — call demand is running unusually high relative to puts. Whether this is pre-earnings speculation on the back of the French deal or simply thin open interest is hard to disentangle, but the direction is clear. The options market is not positioned defensively into this print.
The analyst data is stale — the most recent rating action on record is from Cantor Fitzgerald in February 2025, reiterating Overweight with a $4.00 target, last dated over 14 months ago. At a current price of $1.97, the mean target of $4.25 implies more than 100% upside, but the figure should be treated with caution given its age. The EPS surprise factor score ranks at the 92nd percentile — the company has a strong history of beating consensus estimates. EPS momentum over the past 90 days ranks at the 98th percentile. Earnings variability, though, is real: the last print in early March sent the stock down 17% the following day and 25% over five days. The one before that produced a 3% day-one decline followed by a 26% five-day loss.
The insider angle is worth noting precisely because it runs against the deal-driven optimism. In early March, the CEO, CFO, COO, and Chief Medical Officer all sold shares on the same day — March 12 — at prices around $1.66. The CEO and COO had also sold in the prior week at $2.00. The 90-day net is a sale of approximately 1.07 million shares worth around $1.85 million. These were flagged at low trade-significance scores, suggesting they may be plan-driven dispositions rather than discretionary calls, but the cluster remains visible and the direction is one-way. Soleus Capital Management, meanwhile, disclosed a new 9.8 million share position in late March — representing 5.1% of shares outstanding — which provides an institutional counterweight.
The question going into this evening's print is whether the France contract has changed the revenue trajectory enough to interrupt a recent pattern of disappointment.
See the live data behind this article on ORTEX.
Open CERS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
